What Enveric Biosciences’ EB-003 data reveal about separating benefit from hallucinations [Pharma Device News]
Tuesday, February 24, 2026 1 min read
Key Takeaway: Enveric Biosciences has released new data on its lead candidate EB-003, which shows engagement with Gq and β-arrestin signaling downstream of the 5-HT2A receptor. This data supports the development of EB-003 as a non-hallucinogenic therapy for treating depression and anxiety. The company is currently advancing EB-003 through IND-enabling studies.
Price reaction · baseline $2.06 (2026-02-23 close) · hit pre-market · 4 other ENVB headline(s) in the window, move may be shared
day 0 close
+6.8%
day 1 · peak
+16.5%
day 3
+14.1%
Market Sentiment Analysis
POSITIVE FACTORS
EB-003 shows promising engagement with Gq and β-arrestin signaling.
The therapy aims to be non-hallucinogenic, targeting depression and anxiety.
Enveric is advancing EB-003 through IND-enabling studies.
Full Press Release Details
Enveric Biosciences reported new mechanistic data showing that its lead neuropsychiatric candidate EB-003 engages both Gq and β-arrestin signaling downstream of the 5-HT2A receptor, based on proprietary bioluminescence resonance energy transfer assays. The disclosure comes as the U.S.-based biotechnology firm advances EB-003 through IND-enabling studies with the stated goal of developing a non-hallucinogenic neuroplastogenic therapy for depression and anxiety.
Full Article >>
Frequently Asked Questions
What is EB-003 developed for?
EB-003 is being developed as a non-hallucinogenic therapy for depression and anxiety.
What signaling does EB-003 engage?
EB-003 engages both Gq and β-arrestin signaling downstream of the 5-HT2A receptor.
What studies is EB-003 currently undergoing?
EB-003 is advancing through IND-enabling studies.
What type of therapy is EB-003?
EB-003 is a neuroplastogenic therapy aimed at treating neuropsychiatric conditions.